HCSG

• Net income was $22.7 million, or $0.32 diluted EPS, compared to a net loss of $32.4 million in Q2 2025.
• Cash flow from operations was $21.9 million; excluding the change in payroll accrual, it was $27.9 million.
• The company repurchased $20.9 million of stock in Q2 2026 under its $75.0 million repurchase plan.
• Management reaffirmed its 2026 mid-single-digit growth outlook.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• The non-binding Say on Pay proposal passed with 61,059,063 votes for, 1,305,516 against, and 135,153 abstentions.
• Shareholders ratified Grant Thornton LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026, with 64,821,277 votes for.
• An amendment to the 2020 Omnibus Plan to increase available shares by 2,500,000 was approved with 59,690,433 votes for.
• Approximately 68,954,000 shares were outstanding and entitled to vote as of the March 30, 2026 record date.

5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• Net income was $26.1 million and diluted EPS was $0.37 for the first quarter of 2026.
• Cash flow from operations was $43.7 million; excluding the change in payroll accrual, it was $23.4 million.
• The company repurchased $24.0 million of its common stock in the first quarter and has 9.2 million shares remaining under its February 2026 authorization.
• The company reiterated its 2026 mid-single-digit revenue growth outlook.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Healthcare Services Group, Inc. entered into a Second Amendment to its existing Credit Agreement on April 7, 2026.
• The Second Amendment extends the maturity date of the Credit Agreement to April 7, 2031.
• The Credit Agreement is a $300,000,000 facility with PNC Bank, National Association as administrative agent.
• All other terms of the Credit Agreement remain in full force and effect.

1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits

• Net income was $59.1 million ($0.81 diluted EPS) for the year and $31.2 million ($0.44 diluted EPS) for the quarter.
• Cash flow from operations was $145.0 million for the year and $17.4 million for the quarter; excluding payroll accrual changes, $164.1 million and $36.4 million, respectively.
• Completed $50.0 million share repurchase plan and authorized a new $75.0 million, 12-month program.
• 2026 outlook: expects mid-single-digit revenue growth; goals to manage cost of services in the 86% range and SG&A in the 9.5%-10.5% range.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Net income was $43.0 million and diluted EPS was $0.59, including a $0.361 benefit primarily related to the Employee Retention Credit (ERC).
• Cash flow from operations was $71.3 million; excluding the change in payroll accrual, it was $87.1 million, including a $31.8 million ERC benefit.
• The company repurchased $27.3 million of common stock in Q3 under a $50.0 million 12-month repurchase plan.
• Management expects to manage cost of services in the 86% range and SG&A in the 9.5% to 10.5% range near term.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Net loss was $32.4 million, or $0.44 per diluted share, including a $0.65 per share non-cash charge related to the Genesis HealthCare restructuring.
• Cash flow from operations was $28.8 million; excluding the change in payroll accrual, it was $8.5 million, up $10.9 million year over year.
• The company raised its 2025 cash flow from operations forecast (excluding payroll accrual change) to $70.0-$85.0 million from $60.0-$75.0 million.
• The company announced a $50.0 million, 12-month share repurchase plan under its February 2023 authorization.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• HCSG provides services to 164 Genesis facilities and expects to continue its contractual relationship without disruption in service or payments.
• As of the petition date, HCSG's estimated accounts and notes receivable balances from Genesis, net of reserves, were $50.0 million and $14.4 million, respectively.
• HCSG estimates second quarter non-cash charges of approximately $0.62 per share and third quarter non-cash charges of approximately $0.03 to $0.04 per share due to the Genesis filing.
• HCSG reiterates its 2025 expectations of mid-single digit revenue growth and $60.0 to $75.0 million of cash flow from operations (excluding change in payroll accrual).

7.01 Regulation FD Disclosure